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Clusters of meningococcal disease caused by a hyper-
invasive lineage of Neisseria meningitidis, the ST11 com-
plex, bearing a serogroup C polysaccharide capsule, have
been prominent in Europe and North America since the
early 1990s. This situation has led to expensive public
health measures for outbreak control and, finally, to the
introduction of a serogroup C glyconjugate vaccine into the
primary immunization schedule in the United Kingdom and
elsewhere. ST11 complex meningococci may also express
serogroup W135 polysaccharide capsules. We investigated
the level of population immunity to this hyperinvasive clone
in association with the appearance of outbreaks of
meningococcal disease in southern British Columbia. We
found that most adults and almost all children were appar-
ently susceptible to infection with ST11 complex meningo-
cocci bearing both C and W135 polysaccharide capsules,
which suggests that a vaccine program directed against
only serogroup C meningococci may be insufficient to pre-
vent hyperinvasive ST11 disease.
I
n 1919, George Heist and co-workers established that
clotted blood from different persons varied in its ability
to kill Neisseria meningitidis in a capillary tube. When
Heist, whose blood had no bactericidal activity, acquired
N. meningitidis infection, the link between serum bacteri-
cidal activity and resistance to meningococcal infection
was proven (1). Nearly half a century later, Goldschneider
et al. found that <20% of infants 1 year of age had
anti–serogroup C meningococcal bactericidal activity in
their blood, but >60% of teenagers and 75% of adults had
protective titers (2). Disease rates were inversely related to
the population bactericidal titers, with high rates of disease
in young children and low rates in adults.
Groups of genetically related meningococci can be iden-
tified by using the electrophoretic mobility of cytoplasmic
proteins (electrophoretic type; ET) or by nucleotide
sequencing of “housekeeping” genes (sequence type; ST).
During the 1990s, a clone of serogroup C N. meningitidis
(ET-37 complex; ST11 complex) was responsible for out-
breaks of meningococcal disease in the United States,
Canada, and Europe, predominantly affecting teenagers and
young adults and leading to repeated and massive public
health interventions (3). In 1999, disease attributed to this
clone led to serogroup C glyconjugate vaccine’s introduc-
tion into the primary immunization schedule in the United
Kingdom (4). From December 2000 to April 2001, a clus-
ter of seven cases of invasive serogroup C meningococcal
infection occurred in a community of 120,000 in southern
British Columbia, Canada; five of the seven cases were in
persons 18–27 years of age, which raises the possibility that
more susceptible persons were found in this population
than were previously inferred from data described by
Goldschneider et al. 30 years ago (2).
During the 1990s, most ST11 complex N. meningitidis
isolates in Canada bore an α2-9 N-acetyl neuraminic acid
(serogroup C) capsule, but recent epidemics of meningo-
coccal disease, particularly in Africa, have been associated
with ST11 meningococci bearing the W135 capsule. This
finding suggests that this hyperinvasive lineage might also
spread to populations with low levels of population immu-
nity against W135 capsule-bearing organisms. In addition,
ST11 meningococci bearing serogroup B, and occasional-
ly Y capsules, also occur (5). We examined population
immunity to ST11 complex meningococci bearing
serogroup C or W135 polysaccharide capsules.
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We obtained serum specimens from 175 healthy persons
from southern British Columbia (Table) after the study pro-
tocol was reviewed by the University of British Columbia
Clinical Research Ethics Board. Using these serum speci-
mens, we examined the SBA, the ability of serum to kill
meningococci when mixed with exogenous complement,
against three target strains of N. meningitidis,
AOBZ1379(c) (the outbreak clinical isolate from British
Columbia; C:2a,P1.5; ET15), Z1582/FC978 (a Canadian
clinical isolate from 2000 bearing the W135 capsule,
W135:2a:P1.5,2) and C11 (60E; C:16:P1.7-1,1, a standard
reference strain [2]), according to standard methods by
using baby rabbit complement (Pel-Freeze Inc., Rodgerson,
AR) as the exogenous source of complement (6). The high-
est serum concentration tested in the assay was 1:4, and a
titer of 1:2 was assigned to sera with <50% killing at this
concentration. The three bacterial strains were character-
ized by multilocus sequence typing, which confirmed the
sequence-types as ST11, ST11, and ST345, respectively.
We defined protection against serogroup C N. meningitidis
as a serum bactericidal titer of >1:8 (4,7). Incidence data for
rates of meningococcal disease were obtained from the
British Columbia Center for Disease Control, Vancouver,
Canada (Figure 1). The data are reported as geometric
mean titers (GMTs) and as a  percentage of the population
higher than the protective threshold.
Results
The GMT of the bactericidal antibody against the out-
break strain of serogroup C, ST11 complex N. meningitidis
was 1:2 in serum specimens from all children <18 years of
age who were studied. In the group 19–29 years of age, the
GMT rose to 1:4 and reached 1:7 in adults >30 years of age
(Table). Three percent of children <18 years, and 19% of
adults >19 years of age (median age 33 years), had serum
bactericidal titers above or equal to the “protective” level
(1:8) against this outbreak strain (Figure 1, Table). These
data correlated closely with titers obtained by using strain
C11, the standard reference strain used in serogroup C bac-
tericidal assays (Figure 2). The reference serum CDC1992
(National Institutes for Biological Standards and Control)
also produced identical SBA titers with both meningococ-
cal strains.
The GMT of bactericidal antibody against the W135
strain of N. meningitidis rose steadily from 1:4 in those 18
months of age to 1:8, 1:16, 1:24, and 1:20 in those aged
4–6 years, 11–12 years, 16–18 years, and >19 years,
respectively (Table). Sera tested from 20% of infants had
bactericidal activity against the serogroup W135 ST11
complex organism, with titers >1:8 in up to 40% of serum
samples from persons in the second decade of life and 44%
in serum from adults. Rates of meningococcal disease in
the population were inversely related to the population lev-
els of bactericidal antibody for both serogroup C and
serogroup W135 cases (Figure 1, Table).
Conclusions
This study suggests that population immunity against
hyperinvasive lineages of meningococci are low in a North
American population. Protective serum bactericidal  titers
were present in 3% of children <18 years of age and 19%
of adults (median age 33) against the outbreak strain of
serogroup C, ST11 complex N. meningitidis (Figure 1).
These bactericidal titers were low even though we used a
complement source (baby rabbit serum) that is associated
with higher SBAtiters than the human complement used in
Goldschneider et al.’s study in the 1960s, which found
considerably higher levels of protection (2). Of note, 40%
of meningococcal disease in the 1990s in Canada was
caused by serogroup C meningococci (8). To exclude the
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Figure 1. Incidence (cases/100,000/year) of meningococcal dis-
ease (average rates 1985–2000) in relation to serogroup C and
W135 bactericidal antibody titers in British Columbia against a
local ST11 outbreak isolate (AOBZ1379) and Z1582/FC978 (a
Canadian clinical isolate from 2000 bearing the W135 capsule),
respectively.
Figure 2. Correlation between bactericidal titers against an out-
break strain of serogroup C meningococcus (AOBZ1379) from
southern British Columbia and the standard reference strain C11
from 27 serum specimens.possibility that the outbreak strain was more resistant to
serum bactericidal activity, we compared these data with
those obtained by using C11, the serogroup C meningo-
coccus used in 1969 by Goldschneider et al.; however, we
found a close correlation (r = 0.97) between strains, which
indicates no differences in serum resistance attributable to
the different strains (Figure 2). Since these strains belong
to different sequence types and they carry different sub-
capsular outer membrane proteins (C:16:P1.7-1,1 versus
C:2a:P1.5), these data may indicate that antibodies against
their common antigen (the serogroup C capsule) are more
important than subcapsular antigens in the SBA. However,
other subcapsular proteins common to both isolates may
not have been identified, which could be responsible for
this observation. By contrast, no correlation was seen (r =
0.2) between SBA titers achieved with 60E and
Z1582/FC978, the ST11 W135 isolate, even though both
isolates shared the same major outer membrane proteins
(C:2a:P1.5); this finding further supports the importance of
anticapsular functional antibodies in this assay.
Before routine immunization in the United Kingdom
with serogroup C glyconjugate meningococcal vaccine
was begun, Trotter et al. found bactericidal titers >1:8 in
10% to 20% of infants and 25% of adults (9). Similarly,
Jones et al., found that 10% of university students
appeared to have protective serum bactericidal levels (10).
These U.K. findings are similar to our Canadian data that
suggest that population immunity against serogroup C
meningococcus may now be lower than previously
described in countries without an immunization program. 
We also found that 20% of infants had serum bacterici-
dal activity against the serogroup W135 ST11 complex
organism, with titers >1:8 in up to 40% in serum speci-
mens from persons in the second decade of life and 44% in
serum specimens from adults. The importance of anti-
serogroup W135 serum bactericidal titers for protection is
not well defined, but, extrapolating from serogroup C data,
our results may indicate that 60%–80% of persons are sus-
ceptible to W135 disease. Less than 5% of laboratory-con-
firmed cases of invasive meningococcal disease in British
Columbia are attributable to serogroup W135, but epidem-
ic disease caused by ST11 complex organisms that bear the
W135 capsule has been recognized in recent years and
found to be associated with travel (11) and sub-Saharan
African populations (12). Meningococci bearing the W135
polysaccharide capsule have been a relatively infrequent
cause of sporadic cases of meningococcal disease in the 30
years since the first descriptions of this serogroup from
cases in the U.S. army (13,14). However, in 2000 and
2001, an outbreak of disease occurred among pilgrims
traveling to Mecca in Saudi Arabia for the annual hajj pil-
grimage (14,15). This outbreak was caused by serogroup
W135 meningococci from the ST11 (ET-37) complex (16),
which was previously associated with hyperinvasive
serogroup C disease. Since 2000, ST11 complex serogroup
W135 meningococci have also appeared in sub-Saharan
Africa and caused large epidemics (17). The association of
epidemics of disease with meningococci of the hyperinva-
sive ST11 lineage that bears the W135 capsule is a cause
for concern for populations with limited population immu-
nity to these meningococci.
Figure 1 shows an apparent paradox: although the dis-
ease rate is decreasing substantially in persons <18 months
to 11–12 years, little serologic evidence exists of a parallel
rise in protection, i.e., the geometric mean SBA titers are
almost constant, and the percentage of children with SBA
titers  <1:8 in all age groups up to those 16–18 years
remains low. This finding could indicate that SBA lacks
sensitivity (perhaps protection occurs before a titer of 1:8
is reached) or that protection rises through immune mech-
anisms other than the bactericidal combination of antibody
and complement (such as osponophagocytosis). Adecrease
in exposure to serogroup C meningococci or a reduction in
other cofactors that lead to invasive disease may also occur
in this age group. 
ST11 lineage meningococci may also bear serogroup B
capsules, and evidence exists that a switch between
serogroups may occur naturally in populations (18,19),
perhaps a process that is favored by population immunity.
Whether immunization with vaccines that target serogroup
C capsule–bearing ST11 complex meningococci will favor
the evolution of B or W135 ST11 complex bacteria in the
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of serogroup B ST11 complex meningococci has been
reported in the United Kingdom since the serogroup C gly-
conjugate vaccine was introduced in 1999. However, in
Spain, ST11 serogroup B meningococci have emerged
since vaccine introduction, which raises the possibility
that, in some circumstances, immunologic pressure on
meningococcal populations by vaccine may lead to cap-
sule switching (20).
Recent data after the serogroup C glyconjugate vaccine
was implemented in the United Kingdom strongly suggest
that SBA titers >1:8 are required for protection against
serogroup C meningococcal disease (4,7). Data presented
here indicate that a high proportion of adults, and almost
all children, may be susceptible to disease caused by the
hyperinvasive ST11 clone of serogroup C lineage that is
prevalent in North America. These findings support the
value of the childhood immunization program with
serogroup C meningococcal glyconjugate vaccines, imple-
mented in British Columbia, Canada, since September
2003. However, the propensity of this clone to express
capsular polysaccharides other than serogroup C, includ-
ing W135, and the apparently low population immunity for
bacteria bearing the W135 capsule suggest that monova-
lent serogroup C vaccines may be insufficient to control
this widely distributed hyperinvasive lineage of meningo-
coccus, the ST11 complex.
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